Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: Discordance between expression and function

Attaya Suvannasankha, H. Minderman, K. L. O'Loughlin, T. Nakanishi, W. R. Greco, D. D. Ross, Maria R. Baer

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Data on breast cancer resistance protein (BCRP, MXR, ABCG2) expression in acute myelold leukemia (AML) have been inconsistent, possibly due to use of different assays in different studies. BCRP mRNA was studied by the reverse-transcription polymerase chain reaction and BCRP protein expression (BXP-21, BXP-34 or anti-ABCG2 antibody, with anti-CD34 and anti-CD33) and function (fumitremorgin C modulation of mitoxantrone retention) by flow cytometry in eight cell lines and in pretreatment blasts from 31 AML patients. BCRP mRNA levels, antibody staining and function correlated strongly in cell lines (Pearson r values, 0.73-0.97), but not in AML samples. AML sample BCRP mRNA levels were between those in parental 8226 and 35-fold mitoxantrone-resistant 8226/MR20 cells in all but one case, and BCRP mRNA had the wild-type sequence at codon 482 in all. In AML, unlike in cell lines, BCRP protein expression or function, when present, was only detected in small subpopulations. BCRP mRNA and protein expression did not correlate, nor did staining with different BCRP antibodies, and function did not correlate with mRNA nor protein expression. Presence of BCRP only in subpopulations and discordance among BCRP measurements suggest complex biology of BCRP in AML and incomplete modeling by cell lines.

Original languageEnglish
Pages (from-to)1252-1257
Number of pages6
JournalLeukemia
Volume18
Issue number7
DOIs
StatePublished - Jul 2004

Fingerprint

Acute Myeloid Leukemia
Leukemia
Breast Neoplasms
Messenger RNA
Cell Line
Mitoxantrone
Proteins
Staining and Labeling
Antibodies
Codon
Reverse Transcription
Anti-Idiotypic Antibodies
Flow Cytometry
Polymerase Chain Reaction

Keywords

  • Acute myeloid leukemia
  • Breast cancer resistance protein
  • Multidrug resistance

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Suvannasankha, A., Minderman, H., O'Loughlin, K. L., Nakanishi, T., Greco, W. R., Ross, D. D., & Baer, M. R. (2004). Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: Discordance between expression and function. Leukemia, 18(7), 1252-1257. https://doi.org/10.1038/sj.leu.2403395

Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia : Discordance between expression and function. / Suvannasankha, Attaya; Minderman, H.; O'Loughlin, K. L.; Nakanishi, T.; Greco, W. R.; Ross, D. D.; Baer, Maria R.

In: Leukemia, Vol. 18, No. 7, 07.2004, p. 1252-1257.

Research output: Contribution to journalArticle

Suvannasankha, Attaya ; Minderman, H. ; O'Loughlin, K. L. ; Nakanishi, T. ; Greco, W. R. ; Ross, D. D. ; Baer, Maria R. / Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia : Discordance between expression and function. In: Leukemia. 2004 ; Vol. 18, No. 7. pp. 1252-1257.
@article{ef0f9ceaaeb24137a46f6651a983d70b,
title = "Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: Discordance between expression and function",
abstract = "Data on breast cancer resistance protein (BCRP, MXR, ABCG2) expression in acute myelold leukemia (AML) have been inconsistent, possibly due to use of different assays in different studies. BCRP mRNA was studied by the reverse-transcription polymerase chain reaction and BCRP protein expression (BXP-21, BXP-34 or anti-ABCG2 antibody, with anti-CD34 and anti-CD33) and function (fumitremorgin C modulation of mitoxantrone retention) by flow cytometry in eight cell lines and in pretreatment blasts from 31 AML patients. BCRP mRNA levels, antibody staining and function correlated strongly in cell lines (Pearson r values, 0.73-0.97), but not in AML samples. AML sample BCRP mRNA levels were between those in parental 8226 and 35-fold mitoxantrone-resistant 8226/MR20 cells in all but one case, and BCRP mRNA had the wild-type sequence at codon 482 in all. In AML, unlike in cell lines, BCRP protein expression or function, when present, was only detected in small subpopulations. BCRP mRNA and protein expression did not correlate, nor did staining with different BCRP antibodies, and function did not correlate with mRNA nor protein expression. Presence of BCRP only in subpopulations and discordance among BCRP measurements suggest complex biology of BCRP in AML and incomplete modeling by cell lines.",
keywords = "Acute myeloid leukemia, Breast cancer resistance protein, Multidrug resistance",
author = "Attaya Suvannasankha and H. Minderman and O'Loughlin, {K. L.} and T. Nakanishi and Greco, {W. R.} and Ross, {D. D.} and Baer, {Maria R.}",
year = "2004",
month = "7",
doi = "10.1038/sj.leu.2403395",
language = "English",
volume = "18",
pages = "1252--1257",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia

T2 - Discordance between expression and function

AU - Suvannasankha, Attaya

AU - Minderman, H.

AU - O'Loughlin, K. L.

AU - Nakanishi, T.

AU - Greco, W. R.

AU - Ross, D. D.

AU - Baer, Maria R.

PY - 2004/7

Y1 - 2004/7

N2 - Data on breast cancer resistance protein (BCRP, MXR, ABCG2) expression in acute myelold leukemia (AML) have been inconsistent, possibly due to use of different assays in different studies. BCRP mRNA was studied by the reverse-transcription polymerase chain reaction and BCRP protein expression (BXP-21, BXP-34 or anti-ABCG2 antibody, with anti-CD34 and anti-CD33) and function (fumitremorgin C modulation of mitoxantrone retention) by flow cytometry in eight cell lines and in pretreatment blasts from 31 AML patients. BCRP mRNA levels, antibody staining and function correlated strongly in cell lines (Pearson r values, 0.73-0.97), but not in AML samples. AML sample BCRP mRNA levels were between those in parental 8226 and 35-fold mitoxantrone-resistant 8226/MR20 cells in all but one case, and BCRP mRNA had the wild-type sequence at codon 482 in all. In AML, unlike in cell lines, BCRP protein expression or function, when present, was only detected in small subpopulations. BCRP mRNA and protein expression did not correlate, nor did staining with different BCRP antibodies, and function did not correlate with mRNA nor protein expression. Presence of BCRP only in subpopulations and discordance among BCRP measurements suggest complex biology of BCRP in AML and incomplete modeling by cell lines.

AB - Data on breast cancer resistance protein (BCRP, MXR, ABCG2) expression in acute myelold leukemia (AML) have been inconsistent, possibly due to use of different assays in different studies. BCRP mRNA was studied by the reverse-transcription polymerase chain reaction and BCRP protein expression (BXP-21, BXP-34 or anti-ABCG2 antibody, with anti-CD34 and anti-CD33) and function (fumitremorgin C modulation of mitoxantrone retention) by flow cytometry in eight cell lines and in pretreatment blasts from 31 AML patients. BCRP mRNA levels, antibody staining and function correlated strongly in cell lines (Pearson r values, 0.73-0.97), but not in AML samples. AML sample BCRP mRNA levels were between those in parental 8226 and 35-fold mitoxantrone-resistant 8226/MR20 cells in all but one case, and BCRP mRNA had the wild-type sequence at codon 482 in all. In AML, unlike in cell lines, BCRP protein expression or function, when present, was only detected in small subpopulations. BCRP mRNA and protein expression did not correlate, nor did staining with different BCRP antibodies, and function did not correlate with mRNA nor protein expression. Presence of BCRP only in subpopulations and discordance among BCRP measurements suggest complex biology of BCRP in AML and incomplete modeling by cell lines.

KW - Acute myeloid leukemia

KW - Breast cancer resistance protein

KW - Multidrug resistance

UR - http://www.scopus.com/inward/record.url?scp=3142663295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3142663295&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2403395

DO - 10.1038/sj.leu.2403395

M3 - Article

C2 - 15208643

AN - SCOPUS:3142663295

VL - 18

SP - 1252

EP - 1257

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 7

ER -